Introduction
Hypoxia, a characteristic of many solid cancers, develops from an imbalance between oxygen consumption and oxygen supply. While hypoxia is an important driver of tumor invasion and metastasis as well as resistance to therapy (1) , there is limited knowledge on the contribution of hypoxia to tumor cell escape from destruction by innate and adaptive immune effector mechanisms.
Immune escape in cancer is a multifaceted process resulting from the suppression of immune effector mechanisms and/or the acquisition of intrinsic tumor cell resistance to the cytotoxic activity of immune effectors. Hypoxia can influence these aspects of immune escape by modifying the intrinsic properties of tumor cells and of the stromal compartment. Here we review some of the mechanisms by which hypoxia contributes to immune escape in cancer.
Furthermore, we propose that activation of cyclic guanosine monophosphate (cGMP) signalling in cancer cells, via administration of low doses of nitric oxide (NO) mimetic drugs, may be a novel therapeutic approach to interfere with certain mechanisms of immune escape.
Hypoxia-induced release of immunosuppressive molecules by tumor cells
Upon exposure to hypoxia, tumor cells release a variety of immunosuppressive molecules. For example, in the severely hypoxic tumor microenvironment dying cells release ATP that is metabolized to adenosine by CD73 and CD39 (2) . Soluble adenosine in the extracellular matrix binds specific receptors on T cells to increase their intracellular levels of cAMP, which in turn suppresses T cell functions (3) . Tumor-derived cytokines released under hypoxic conditions, such as IL-10 and TGF-, induce the differentiation of tumor-associated macrophages (TAMs) Interestingly, emerging evidence links hypoxia-induced angiogenesis with immune tolerance (6, 7) . Hypoxia drives angiogenesis within the tumor microenvironment by inducing the secretion of vascular endothelial growth factor (VEGF) and other pro-angiogenic molecules by tumor cells. Tumor-derived VEGF suppresses the maturation of DCs and blocks the presentation of tumor associated antigens to helper T cells, thereby promoting immune escape (6) . Moreover, in response to tumor-derived VEGF, DCs increase their expression of the Programmed Death Ligand 1 (PD-L1 or B7-H1), a negative regulator of T cell function (7) . VEGF promotes the accumulation of myeloid derived suppressor cells (MDSCs) in tumor tissues and secondary lymphoid organs (6) . MDSCs are potent suppressors of anti-cancer T cell responses and also contribute to tumor progression by releasing factors that promote angiogenesis and metastasis (for a review on MDSCs see reference (8) ). Consequently, VEGF is a potential target for immune therapy. In support of this, anti-VEGF therapy was shown to be associated with an increase in activated DCs and T cell function in cancer patients (9) . However, targeting VEGF as an immunotherapeutic approach may lead to tumor hypoxia via inhibition of angiogenesis, thereby resulting in the activation of other hypoxia-induced immune escape pathways. (10) . In an ovarian cancer model, hypoxia was shown to promote the recruitment of T regs via increased tumor cell expression of CCL28 (11). T regs in turn can also secrete VEGF, thereby contributing to the VEGF pool in the tumor microenvironment that contributes to immune tolerance (11).
Tumor cells can also produce galectin-1 and galectin-3 to induce apoptosis of activated lymphocytes (12, 13) . In melanoma patients, there was a strong correlation between expression of galectin-3 and apoptosis of tumor infiltrating lymphocytes (TILs) (12) . In Wilms tumors and Schwannomas, galectin-3 was shown to co-localize with hypoxia-inducible factor 1 (HIF-1α) (14) , a heterodimeric transcriptional regulator of adaptations to hypoxia, consisting of an oxygen-regulated HIF-1α subunit and a constitutively expressed HIF-1β subunit. Additionally, it was reported that galectin-1 expression is transcriptionally regulated by HIF-1 in colorectal cancers (15) and head and neck squamous cell carcinomas (16) .
Hypoxia was also shown to induce immunosuppression by up-regulating COX-2 expression in tumor cells; and HIF-1-mediated up-regulation of COX-2 increased colorectal tumor cell survival and VEGF production (17) . COX-2 is a pro-inflammatory enzyme that converts arachidonic acid into prostaglandin E 2 (PGE 2 ). The latter causes immunosuppression by increasing adenosine/cAMP signalling in effector T cells (18) . PGE 2 secreted from tumor cells can also inhibit anti-tumor immunity by inhibiting the maturation of DCs (19) . Also, PGE 2 enhances the suppressive activity of T regs and supports the differentiation of T regs (20) . 
Direct effects of hypoxia on immune effectors
Hypoxia can also directly impair anti-tumor immune responses. For example, hypoxia in the tumor microenvironment can induce the release of VEGF by M2 macrophages (24) .
Furthermore, TAMs suppress T cell function in a manner dependent on HIF-1 (25) , and TAMs in hypoxic regions of tumors exhibit increased expression of M2 promoting molecules, such as TGF-β (26) . Hypoxia inhibits the in vitro cytolytic activity of other immune effectors such as the NK cell-mediated killing of hepatocellular carcinoma cells and multiple myeloma cells (27, 28) .
Hypoxia was shown to decrease T cell survival (29) , and incubation of naive T cells under hypoxia decreases their secretion of the trophic cytokine IL-2 in a HIF-1-dependent manner (30) . CD4 + and CD8 + T cells derived from HIF-1 deficient mice exhibit increased proliferation, produce higher levels of interferon γ, and display increased anti-tumor responses (31) . HIF-1
was also shown to mediate T reg differentiation via increased expression of FoxP3 (32) . Increased It is important to note that not all of the reported effects of hypoxia on T cells are detrimental to their function. Hypoxia was reported to up-regulate CD137, a member of the TNF receptor family that is known for its co-stimulatory activity on T cells (38) . Expression of CD137 on activated mouse T cells was shown to be stimulated by hypoxia (39) , and tumors from HIF-1α-deficient mice exhibited undetectable CD137 + TILs (39) . In tumor growth assays, hypoxia induced the activation of T-cells via the up-regulation of surface CD137 in a HIF-1-dependent manner, which in turn resulted in improved immune response and slower tumor growth (39) .
Hypoxia induces immune tolerance via regulation of immune checkpoints
In addition to decreasing the cytolytic potential of immune effectors, hypoxia increases the + cytotoxic T cells (54) .
Regulation of immune tolerance via hypoxia-induced autophagy
Cancer cells often rely on autophagy as a mechanism of survival under conditions of stress including hypoxia, nutrient starvation, growth factor withdrawal, and chemotherapy (55, 56) . CAN-14-2598 mature DCs, possibly due to induction of autophagy (64) . Hypoxia-induced autophagy in antigen presenting cells infiltrating a tumor can occur via toll-like receptor (TLR) signalling (65) . Together, the above findings indicate a dual role for autophagy in cancer immune escape.
Therefore, immunotherapeutic strategies designed to target autophagy will need to consider its impact on the immune system.
Nitric oxide/cGMP-mediated inhibition of hypoxia-induced immune escape
Our research over the last 15 years has revealed that classical NO signalling involving cGMP production functions as an O 2 -sensing mechanism playing a key role in tumor cell adaptations to hypoxia (42, 43, 48, (66) (67) (68) (69) . Based on our findings, we postulated that an important aspect of the mechanism by which cancer cells adapt to hypoxia involves inhibition of endogenous NO/cGMP signalling. This concept is supported by results showing that NO mimetics (e.g. glyceryl trinitrate (GTN), DETA/NO) at very low concentrations (ηM -ρM) known to solely activate sGC inhibit malignant adaptations to hypoxia, i.e. increased invasiveness, metastatic ability and drug resistance (66) (67) (68) (69) . Moreover, since NO production is dependent on O 2 availability, endogenous NO generation is severely limited in cells exposed to hypoxia (70, 71) . This is despite the fact that hypoxia was shown to increase the expression of inducible nitric oxide synthase (iNOS) in the same cells (RAW 264.7 macrophages) (71) . We previously reported Author Manuscript Published OnlineFirst on October 24, 2014; DOI: 10.1158/0008-5472.CAN- phenotypes are at least partly mediated via inhibition of HIF-1 transcriptional activity. This conclusion is based on evidence that NO mimetics, including the cGMP analogue 8-bromocGMP, as shown by us (43) , inhibit the accumulation of HIF-1 in cells exposed to hypoxia (43, 72) . Our research has also revealed that NO mimetics interfere with the HIF-1-mediated upregulation of ADAM10 expression involved in the shedding of MICA from the tumor cell surface and resistance to immune mediated lysis (43) (Figure 1) . In that same study, treatment of mice 
